PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
PTC Therapeutics expects to provide 2027 sales guidance for Sephience in January. Executives are seeking to show that the drug’s strong first year of sales can be sustained, amid discussion of potential exceeding $2 billion.
Why it matters — The upcoming guidance will give PTCT watchers information about the company’s expectations for Sephience’s sales trajectory.